Geron Corp. (GERN) Reports that hESC-Derived Oligodendrocyte Progenitor Cells Reduced Cervical Spinal Cord Injury
Geron Corporation (NASDAQ: GERN) today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when transplanted into a rodent model of cervical spinal cord injury, reduced tissue damage within the lesion and improved recovery of locomotor function. These data provide preclinical proof-of-concept for the use of GRNOPC1, Geron's hESC-derived oligodendrocyte progenitor product, in patients with cervical spinal cord injuries. Over half of the 11,000 human spinal cord injuries that are sustained in the U.S. annually are in the cervical region.
Oligodendrocytes have two main functions in the spinal cord; they produce the myelin that wraps around nerve fibers to enable electrical impulse conduction and they produce other molecules (neurotrophic factors) that help to maintain nerve cells. In spinal cord injury oligodendrocytes are lost, resulting in the loss of myelin and death of nerve cells that can cause paralysis below the injury. The present study, conducted in a cervical model of spinal cord injury, adds to previous work in a thoracic model, which has demonstrated that injection of hESC-derived OPCs into the site of injury improved locomotor function with evidence of remyelination of nerve fibers.
The cervical injury model used in this study induced widespread tissue loss resulting in a cavity in the spinal cord. In contrast, there was no cavity in the spinal cord of the rodents that had been injected with hESC-derived OPCs seven days after injury, and the transplant area contained human oligodendrocytes. Further analysis of the injury sites revealed there were significantly more normally myelinated neurons, fewer demyelinated neurons, and importantly, a greater number of preserved motor neurons compared to controls. These data provide in vivo evidence that hESC-derived OPCs may protect the spinal cord from tissue damage induced by injury in addition to having a remyelinating function. Along with these observations was noted a decrease in genes associated with tissue damage and inflammation suggestive of a mechanism in which hESC-OPCs are exerting their tissue-sparing effect.
Critically, the preservation of motor neurons within the spinal cord was shown to correlate with functional recovery. In the cervical injury model forelimb function was compromised. The animals that had received hESC-OPCs showed significantly greater improvement in forelimb stride length and range of motion compared to untreated controls.
Related Categories
Corporate NewsStocks Mentioned
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

stem cell
sol on Nov 11, 2009 10:33 AMRead and educate. This article on Gern proves stem cell is working. You can use your own stem cell to save your life. In the last month there has been 3 surgeries using stem cell. A doctor did a facelift in Miami FL using your own stem cell. Gern along with astm and stem cell stocks are proving now stem cell works. I know because my brother used his own stem to save his life. The sad part he had to go out of the country. Come on US lets get smart and support stem cell stocks. It's happening right now. READ READ111111111